No it's not. It's not about which class of anti-VEGF is better.
This is a question of whether OPT-302 works in synergy with Eylea.
Anti-VEGF C/D will never be a stand alone treatment.
Anti VEGF A/B will always inhibit neovascularisation better than Anti-VEGF C/D.
A/B is the most potent pathway to attack, but it leaves gaps.
OPT-302 fills these gaps.
5 letters = 1 line.
Take patient receiving Eylea for DME who can't improve their BCVA better than 6/15 with glasses.
- They lose their driving licence
Improve the vision of 1 eye by 5 letters (ie, just improve their right eye from 6/15 to 6/12).
- They keep their driving licence.
5 letters can make a huge difference to a patient's life.
No it's not. It's not about which class of anti-VEGF...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
-0.010(1.61%) |
Mkt cap ! $404.3M | |||
| Open | High | Low | Value | Volume |
| 62.5¢ | 62.5¢ | 60.5¢ | $208.1K | 341.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2890 | 61.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 3370 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
61.5¢ |
Change
-0.010 ( 0.69 %) |
||||
| Open | High | Low | Volume | ||
| 62.0¢ | 62.0¢ | 60.5¢ | 17553 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| OPT (ASX) Chart |